Migraine Trial, Recruiting NCT06503328 Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation Condition: Migraine
Back to Migraine

Migraine Trial, Recruiting

NCT06503328
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

As a Healthy Control participant:

  • Adults aged between 18 and 65 years who do not have a headache disorder (occasional tension-type headache is acceptable)

As an Episodic Cluster Headache participant:

  • Adults aged between 18 and 65 years of any gender who have been diagnosed with Episodic Cluster Headache (based on recognised diagnostic guidelines) for at least 1 year before entering the trial

As a Chronic Cluster Headache participant:

  • Adults aged between 18 and 65 years of any gender who have been diagnosed with Chronic Cluster Headache (based on recognised diagnostic guidelines) for at least 1 year before entering the trial

Who may not be able to join:

Healthy Control participants may not be eligible if they:

  • Have a diagnosis of any headache disorder (other than occasional tension-type headache)
  • Have a diagnosed neurological condition
  • Have any other medical condition that the researcher considers clinically significant
  • Are currently pregnant or breastfeeding
  • Have taken anti-inflammatory painkillers (NSAIDs), triptans, or opioid medications in the 24 hours before the study

Episodic or Chronic Cluster Headache participants may not be eligible if they:

  • Have any additional headache diagnosis alongside their cluster headache (other than occasional tension-type headache)
  • Have any other diagnosed neurological condition
  • Have any other medical condition that the researcher considers clinically significant
  • Have been diagnosed with any chronic pain condition of any kind
  • Are currently pregnant or breastfeeding
  • Use substances of abuse

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 00390382380387

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Registry
ClinicalTrials.gov
Start date
1 March 2023
Est. completion
31 December 2024

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

PBMCs gene expression of miR-382-5p

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov